This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yu, D. Articles by Thomas-Tikhonenko, A. Search for Related Content PubMed PubMed Citation Articles by Yu, D. Articles by Thomas-Tikhonenko, A.

Inactivation of Myc in Murine Two-Hit B lymphomas Causes Dormancy with Elevated Levels of Interleukin 10 Receptor and CD20: Implications for Adjuvant Therapies

¹ Department of Pathobiology and ² Biomedical Informatics Core, University of Pennsylvania, Philadelphia, Pennsylvania

Requests for reprints: Andrei Thomas-Tikhonenko, Department of Pathobiology University of Pennsylvania, M/C 6051 3800 Spruce Street, Philadelphia, PA 19104-6051. Phone: 215-573-5138; Fax: 215-746-0380; E-mail: andreit{at}mail.vet.upenn.edu.

Overexpression of c-Myc and inactivation of p53 are hallmarks of human Burkitt's lymphomas. We had previously showed that transduction of murine p53-null bone marrow cells with a Myc-encoding retrovirus is sufficient for B lymphomagenesis. To address the role of Myc in tumor sustenance, we generated lymphomas induced by the Myc-estrogen receptor fusion protein (MycER). Engrafted hosts were continuously treated with the ER ligand 4-hydroxytamoxifen (4-OHT) to allow tumor formation. Subsequent inactivation of MycER via 4-OHT deprivation resulted in tumor stasis but only partial regression. At the cellular level, dormant neoplastic lymphocytes withdrew from mitosis and underwent further B-cell differentiation. Concomitantly, they up-regulated genes involved in lymphocyte proliferation and survival, most notably interleukin 10 receptor (IL10R) and CD20, the target for antibody therapy with Rituxan. We found that overexpression of IL10R affords significant proliferative advantages and in 4-OHT–deprived animals correlates with eventual tumor relapse. Both dormant and relapsing tumors maintain IL10R expression suggesting that they might be sensitive to emerging drugs targeting the IL-10 pathway. Up-regulation of CD20 following Myc inactivation was also observed in immortalized human lymphocytes. Importantly, in this system, Myc^OFFCD20^HIGH cells were more prone to Rituxan-induced apoptosis than Myc^ONCD20^MED. Thus, targeting Myc, while moderately effective on its own, shapes the phenotype of dormant neoplastic cells and sensitizes them to adjuvant molecular therapies.

This article has been cited by other articles:

				T.-C. Chang, L. R. Zeitels, H.-W. Hwang, R. R. Chivukula, E. A. Wentzel, M. Dews, J. Jung, P. Gao, C. V. Dang, M. A. Beer, et al. Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation PNAS, March 3, 2009; 106(9): 3384 - 3389. [Abstract] [Full Text] [PDF]

				D. Yu, M. Carroll, and A. Thomas-Tikhonenko p53 status dictates responses of B lymphomas to monotherapy with proteasome inhibitors Blood, June 1, 2007; 109(11): 4936 - 4943. [Abstract] [Full Text] [PDF]

				K. A. O'Donnell, D. Yu, K. I. Zeller, J.-w. Kim, F. Racke, A. Thomas-Tikhonenko, and C. V. Dang Activation of Transferrin Receptor 1 by c-Myc Enhances Cellular Proliferation and Tumorigenesis Mol. Cell. Biol., March 15, 2006; 26(6): 2373 - 2386. [Abstract] [Full Text] [PDF]

				X.-y. Zhang, L. M. DeSalle, J. H. Patel, A. J. Capobianco, D. Yu, A. Thomas-Tikhonenko, and S. B. McMahon Metastasis-associated protein 1 (MTA1) is an essential downstream effector of the c-MYC oncoprotein PNAS, September 27, 2005; 102(39): 13968 - 13973. [Abstract] [Full Text] [PDF]